ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "APRIL"

  • Abstract Number: L18 • 2019 ACR/ARP Annual Meeting

    A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study

    Di Wu1, Jing Li 2, Dong Xu 2, Wenxiang Wang 3, Lin Li 4, Jianmin Fang 3 and Fengchun Zhang 5, 1Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), 2Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Beijing, China (People's Republic), 3RemeGen, Ltd., Yantai, China (People's Republic), 4RemeGen, Ltd., Beijing, China (People's Republic), 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)

    Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…
  • Abstract Number: 1 • 2018 ACR/ARHP Annual Meeting

    Profiling of B-Cell Related Factors and Its Decoy Receptors in Rheumatoid Arthritis: Potential Clues for Patient Stratification

    Javier Rodríguez-Carrio1,2, Mercedes Alperi-López3, Patricia López1, Francisco Javier Ballina-García4 and Ana Suárez1, 1Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, 2Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain, 3Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, 4Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain

    Background/Purpose: B-cell over-activation plays a key role in the pathogenesis of rheumatoid arthritis (RA), thus being recognized as a therapeutic target. However, the activation of…
  • Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting

    Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis

    Yasuhiro Shimojima1, Dai Kishida2 and Yoshiki Sekijima2, 1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

    Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
  • Abstract Number: 2642 • 2018 ACR/ARHP Annual Meeting

    Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE

    Jinshan Shen1, Orestis Papasouliotis2, Eileen Samy1, Philipp Haselmayer3, Peter Chang4, Victor Ona1 and Amy H. Kao1, 1EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 2Merck Institute for Pharmacometrics, an affiliate of Merck KGaA, Darmstadt, Germany, Lausanne, Switzerland, 3Merck KGaA, Darmstadt, Germany, 4EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA

    Background/Purpose: Atacicept targets the B-cell-stimulators BLyS and APRIL, and is in development for the treatment of patients (pts) with SLE. Here, we integrated non-clinical and…
  • Abstract Number: 2678 • 2018 ACR/ARHP Annual Meeting

    Integrated Safety Profile of Atacicept from All Clinical Studies to Date

    Caroline Gordon1,2, Roberto Bassi3, Peter Chang4, Amy H. Kao3, David Jayne5, David Wofsy6, Victor Ona3 and Patricia Fleuranceau-Morel3, 1Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 4EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, 5Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 6Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: We conducted an integrated analysis of pooled safety data from all 17 atacicept clinical studies to date, across multiple indications, to further define atacicept’s…
  • Abstract Number: 2585 • 2017 ACR/ARHP Annual Meeting

    Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study

    Joan T. Merrill1, Daniel J. Wallace2, Cristina Vazquez-Mateo3, Amy H. Kao3, Patricia Fleuranceau-Morel3, Peter Chang4 and David A. Isenberg5, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, 3EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 4EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, 5Centre for Rheumatology Research, University College London, London, England

    Background/Purpose: Atacicept targets the B-cell stimulating factors, BLyS and APRIL, and has demonstrated a clinical response in SLE patients (pts) with high disease activity (HDA;…
  • Abstract Number: 2586 • 2017 ACR/ARHP Annual Meeting

    Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE

    Orestis Papasouliotis1, Oezkan Yalkinoglu1, Cristina Vazquez-Mateo2, Stephen Wax3, Amy H. Kao2, Peter Chang3, Patricia Fleuranceau-morel2 and Lisa Mahnke2, 1Merck KGaA, Darmstadt, Germany, 2EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA

    Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL, and has been shown to reduce SLE disease activity. Our analyses evaluated the exposure-response and…
  • Abstract Number: 28 • 2017 ACR/ARHP Annual Meeting

    Sapril and Sbcma As Potential Biomarkers of B Cell Hyperactivation in Rheumatoid Arthritis: A Cluster Analysis Approach

    Javier Rodríguez-Carrio1, Mercedes Alperi-López2, Patricia López1, Francisco Javier Ballina-García3 and Ana Suárez1, 1Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, 2Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, 3Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain

    Background/Purpose: B cell compartment plays a key role in the pathogenesis of rheumatoid arthritis (RA). Activation and survival of B cell largely rely on the…
  • Abstract Number: 889 • 2017 ACR/ARHP Annual Meeting

    Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)

    Eric F Morand1, Joan T. Merrill2, Amy H. Kao3, Cristina Vazquez-Mateo3, Stephen Wax4, Peter Chang4, Kishore Pudota3 and David A. Isenberg5, 1Monash University, Melbourne, Australia, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 4EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, 5Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Low disease activity (LDA) in lupus patients is increasingly a goal of treatment.  For instance, Lupus Low Disease Activity State (LLDAS) attainment is associated…
  • Abstract Number: 654 • 2016 ACR/ARHP Annual Meeting

    The Level of B-Cell Active Cytokines and Soluble B-Cell Activating Factor/a Proliferation-Inducing Ligand Receptors in Patients with Primary Sjogren’s Syndrome

    You Jung Ha1, Jaehyung Hur1, Sang Wan Chung1, Eun Ha Kang2, Yeong Wook Song3,4 and Yun Jong Lee5, 1Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, 3WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, The Republic of, 4Department of Internal Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea

    Background/Purpose: Primary Sjögren`s syndrome (pSS) is an autoimmune diseases characterized by lymphocytic infiltration of exocrine glands and dysregulated proliferation and differentiation of B cells. Two…
  • Abstract Number: 1109 • 2015 ACR/ARHP Annual Meeting

    Co-Crystal Structure of TACI and APRIL-BAFF-BAFF Heteromer Suggests That Charged Residues in APRIL and BAFF Dictate Their Receptor Binding Affinities

    Xuliang Jiang1, Thomas Tan2, Klaus Maskos3, Alfred Lammens3, Pascal Schneider4 and Wolf Palinksy5, 1Research and Development Institute, EMD Serono, Billerica, MA, 2EMD Serono Research, Billerica, MD, 3Proteros Biostructures GmbH, Planegg, Germany, 4Biochemistry, University of Lausanne, Epalinges, Switzerland, 5Global Biotech Development, Merck Serono, Aubonne, Switzerland

    Background/Purpose: The human B cell survival factor, B cell activation factor (BAFF), and its closely related homologue, a proliferation-inducing ligand (APRIL), modulate B cell functions…
  • Abstract Number: 1110 • 2015 ACR/ARHP Annual Meeting

    A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells

    Charlotte Hua1, Rachel Audo2, Nataliya Yeremenko3, Dominique Baeten4, Michael Hahne2, Bernard Combe5, Jacques Morel5 and Claire I. Daien5, 1Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, 2IGMM-CNRS UMR5535, Montpellier, France, 3Academic medical center, University of Amsterdam, Amsterdam, France, 41Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 5Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France

    Background/Purpose: B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B-cell functions are impaired in…
  • Abstract Number: 2838 • 2014 ACR/ARHP Annual Meeting

    Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus

    David Wofsy1, Caroline Gordon2, Yong Li3, Stephen D. Wax4 and David Isenberg5, 1Division of Rheumatology, University of California, San Francisco, CA, 2Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 3R&D Global BioStatistics, EMD Serono, Billerica, MA, 4Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, 5Centre for Rheumatology Research, University College Hospital London, London, United Kingdom

    Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulating factors BLyS and APRIL. We previously reported the clinical effects of atacicept in lupus patients…
  • Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting

    Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design

    Joan T. Merrill1, Yong Li2, Stephen D. Wax3 and Christopher Tehlirian4, 1Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2R&D Global BioStatistics, EMD Serono, Billerica, MA, 3Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, 4EMD Serono, Rockland, MA

    Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…
  • Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting

    B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response

    Ioannis Parodis1, Agneta Zickert1, Elisabet Svenungsson2, Vivianne Malmström2 and Iva Gunnarsson1, 1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology